This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Does HealthEquity (HQY) Have the Potential to Rally 31.37% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 31.4% upside potential for HealthEquity (HQY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Three Reasons to Add Ecolab (ECL) Stock to Your Portfolio
by Zacks Equity Research
Ecolab's (ECL) focus on R&D raises optimism about the stock.
3 Amazing Health Service Stocks to Brave "Labordemic" in 2024
by Urmimala Biswas
Here are the three stocks, MEDP, ELV and HQY, which have the potential to shield your portfolio from the impact of healthcare staffing challenges in 2024.
3 Reasons to Retain Nevro (NVRO) in Your Portfolio for Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
5 MedTech Stocks Poised to Continue Their Winning Streaks in 2024
by Zacks Equity Research
Stocks like DexCom Inc. (DXCM), Integer Holdings (ITGR), Penumbra (PEN), Haemonetics (HAE), Health Equity (HAE) and are likely to continue their strong performance in 2024.
McKesson (MCK) Announces Availability of PNH's FDA-Approved Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PNH.
Three Reasons to Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
Here's Why You Should Retain Veeva Systems (VEEV) Stock Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
QuidelOrtho's (QDEL) Latest FDA Nod to Boost Diagnostic Testing
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of the FDA's latest approval is likely to improve clinical care, provide cost savings and deliver sample-to-result molecular testing across all laboratory settings.
Reasons to Add Integer Holdings (ITGR) to Your Portfolio Now
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Veeva Systems (VEEV) Vault Quality Offerings Adopted by Recipharm
by Zacks Equity Research
Veeva Systems' (VEEV) Vault Quality Suite applications are expected to aid Recipharm in boosting its operational efficiencies.
3 Reasons to Add HealthEquity (HQY) Stock to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment
by Zacks Equity Research
The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.
DexCom's (DXCM) G7 CGM Connects With Tandem's Insulin Pump
by Zacks Equity Research
Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.
Molina (MOH) to Pay Lower Price for California Medicare Buyout
by Zacks Equity Research
Molina Healthcare's (MOH) new price for Bright HealthCare's California Medicare business constitutes 23% of the anticipated $1.8 billion premium revenues for 2023.
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
by Zacks Equity Research
QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is a concern.
Here's Why Investors Should Hold Elevance (ELV) Stock for Now
by Zacks Equity Research
Elevance's (ELV) Carelon unit will see growth due to improving performance in post-acute care services and Behavioral Health business.
Boston Scientific (BSX) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.